
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
TOKYO and RAHWAY, N.J., Apr 21, 2026 – (JCN Newswire via SeaPRwire.com) – Merck & Co., Inc., Rahway, NJ, USA […]
















